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Background: Controversy remains about whether depression can be successfully managed after acute coronary syndrome (ACS) and the costs and 
benefits of doing so. Our objective was to determine the effects of providing centralized, patient preference-based, stepped depression care post-
ACS on depressive symptoms and health care costs.
methods: We performed a multicenter randomized controlled trial with 150 patients with elevated depressive symptoms (Beck Depression 
Inventory score >10) 2 to 6 months after an ACS who were recruited and randomized from 7 private and academic ambulatory centers across 
the United States between March 18, 2010 and January 9, 2012. Masked research staff assessed outcomes. The intervention was six months of 
centralized depression care (patient preference for problem-solving treatment, pharmacotherapy, both, or neither), stepped every 6 to 8 weeks, given 
by telephone or the internet (n=73) (active treatment group) compared with locally administered, physician-guided depression care (usual care 
group) (n=77). The main outcome measures were change in depressive symptoms during 6 months and total health care costs.
results: Depressive symptoms decreased significantly more (t = −3.5; P=.01) in the active treatment group (change, −10.1; 95% confidence 
interval (CI), −12.0 to −8.1) than in the usual care group (change, −6.6; 95% CI, −8.5 to −4.8). Although cost was higher ($1110) for active 
treatment than usual care ($414; adjusted difference, +$687; 95% CI, $466 to $909; P<.001), after including all health care costs (ambulatory 
care, hospitalizations, and cardiac procedures), the difference was no longer significant (adjusted difference, −$325; 95% CI, −$2639 to +$1989; 
P=.78).
conclusions: For patients with post-ACS depression, active treatment produced substantial reduction in depression. The depressive symptom 
effect size of 0.59 was approximately double that reported in meta-analyses of other depression treatment trials. This kind of depression care is 
feasible, effective, and cost neutral and should be tested in a large phase 3 pragmatic trial.
